Maravai Lifesciences Holdings (MRVI) Current Deferred Revenue (2020 - 2025)

Maravai Lifesciences Holdings' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $1.6 million for Q2 2025.

• In Q2 2025, Current Deferred Revenue fell 23.63% year-over-year to $1.6 million; the TTM figure through Jun 2025 stood at $1.6 million (down 23.63% YoY), while the FY2024 annual figure was $2.4 million, down 56.82% from the prior year.
• Current Deferred Revenue was $1.6 million for Q2 2025 at Maravai Lifesciences Holdings, down from $2.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $120.7 million in Q1 2021 to a low of $1.6 million in Q2 2025.
• Historically, Current Deferred Revenue has averaged $20.3 million across 5 years, with a median of $5.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue slumped 95.61% in 2022, then climbed 14.58% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $10.2 million in 2021, then sank by 52.99% to $4.8 million in 2022, then advanced by 14.58% to $5.5 million in 2023, then tumbled by 56.82% to $2.4 million in 2024, then plunged by 30.99% to $1.6 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.6 million (Q2 2025), $2.8 million (Q1 2025), and $2.4 million (Q4 2024), per Business Quant data.